Blueprint Medicines Corp · Q2 2022 earnings

Briefing

Blueprint Medicines reported second quarter 2022 results, achieving $36.5 million in total revenues, including $28.5 million in AYVAKIT net product revenues.

Blueprint Medicines reported $36.5 million in total revenues for Q2 2022, including $28.5 million from AYVAKIT. The company is on track to announce topline data from the PIONEER trial in August and has over $1 billion in cash on its balance sheet.

• Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT net product revenues.
• AYVAKIT revenue grew 20% from Q1 2022.
• Plan to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in August 2022.
• Licensed KIT exon 13 inhibitor to IDRx in exchange for a 15 percent Series A preferred equity investment, and the potential to receive up to $217.5 million in development, regulatory, and sales-based milestones and tiered percentage royalties.

Headline financials

Revenue & EPS history

Blueprint Medicines anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AYVAKIT net product revenues. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.